Scholar Rock Holding Corp
SRRK30.650USD
+1.280+4.36%
交易中 （美东）报价延迟15分钟
2.94B总市值
亏损市盈率 TTM
关于 Scholar Rock Holding Corp 公司
Scholar Rock Holding Corporation 是一家生物制药公司。该公司专注于发现、开发和提供用于治疗严重疾病的药物，其中蛋白质生长因子的信号传导起着根本性的作用。其转化生长因子β (TGFb) 超家族生物学、其生长因子激活的新型分子机制使该公司能够开发专有平台，用于开发局部和选择性靶向前体的单克隆抗体。其候选产品 apitegromab 是一种选择性、完全人源化单克隆抗体，其作用机制可抑制骨骼肌中生长因子肌生长抑制素的激活。Apitegromab 正在开发为首个用于治疗脊髓性肌萎缩症 (SMA) 的肌肉靶向疗法。其另一个候选产品 SRK-181 是一种选择性抑制潜伏性 TGFb 激活的抑制剂，正在开发用于治疗癌症。
Scholar Rock Holding Corp简介
公司代码SRRK
公司名称Scholar Rock Holding Corp
上市日期May 24, 2018
CEOMr. David L. Hallal
员工数量196
证券类型Ordinary Share
年结日May 24
公司地址301 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话18572593860
网址https://scholarrock.com/
公司代码SRRK
上市日期May 24, 2018
CEOMr. David L. Hallal
Scholar Rock Holding Corp公司高管
名称
名称/职务
职务
持股
持股变动
Mr. David L. Hallal
Mr. David L. Hallal
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.60M
-11.36%
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
President - Research & Development, Director
President - Research & Development, Director
616.21K
-1.08%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Chief Financial Officer
Chief Financial Officer
600.00K
--
Ms. Caryn Parlavecchio
Ms. Caryn Parlavecchio
Chief Human Resources Officer
Chief Human Resources Officer
155.46K
-1.38%
Ms. Junlin Ho, J.D.
Ms. Junlin Ho, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
96.29K
+1.19%
Ms. Tracey Sacco
Ms. Tracey Sacco
Chief Commercial Officer
Chief Commercial Officer
22.46K
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
21.07K
+11.85%
Ms. Katie Peng
Ms. Katie Peng
Independent Director
Independent Director
18.27K
-5.22%
Dr. Mo Qatanani, Ph.D.
Dr. Mo Qatanani, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.59K
-18.11%
Mr. Joshua Reed
Mr. Joshua Reed
Independent Director
Independent Director
15.73K
+16.53%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. David L. Hallal
Mr. David L. Hallal
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.60M
-11.36%
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
President - Research & Development, Director
President - Research & Development, Director
616.21K
-1.08%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Chief Financial Officer
Chief Financial Officer
600.00K
--
Ms. Caryn Parlavecchio
Ms. Caryn Parlavecchio
Chief Human Resources Officer
Chief Human Resources Officer
155.46K
-1.38%
Ms. Junlin Ho, J.D.
Ms. Junlin Ho, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
96.29K
+1.19%
Ms. Tracey Sacco
Ms. Tracey Sacco
Chief Commercial Officer
Chief Commercial Officer
22.46K
--
收入明细
FY2024
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 10月31日 周五
更新时间: 10月31日 周五
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.34%
Invus Public Equities Advisors, LLC
9.62%
T. Rowe Price Associates, Inc.
9.02%
Samsara BioCapital, LLC
6.04%
BlackRock Institutional Trust Company, N.A.
5.93%
其他
55.05%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.34%
Invus Public Equities Advisors, LLC
9.62%
T. Rowe Price Associates, Inc.
9.02%
Samsara BioCapital, LLC
6.04%
BlackRock Institutional Trust Company, N.A.
5.93%
其他
55.05%
股东类型
持股股东
占比
Investment Advisor
62.58%
Investment Advisor/Hedge Fund
30.21%
Hedge Fund
13.30%
Venture Capital
9.69%
Individual Investor
4.16%
Research Firm
2.84%
Sovereign Wealth Fund
1.22%
Pension Fund
1.03%
Bank and Trust
0.26%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
483
118.67M
123.52%
-2.02M
2025Q2
466
118.81M
123.62%
+4.48M
2025Q1
456
113.90M
119.97%
-666.42K
2024Q4
421
111.65M
118.02%
+13.32M
2024Q3
371
94.78M
117.45%
-2.79M
2024Q2
357
92.97M
115.37%
-3.23M
2024Q1
328
91.48M
116.64%
-131.69K
2023Q4
308
87.39M
122.16%
+15.93M
2023Q3
283
62.18M
111.86%
-162.68K
2023Q2
284
59.23M
108.43%
+2.68M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
13.78M
14.34%
+39.58K
+0.29%
Jun 30, 2025
Invus Public Equities Advisors, LLC
9.25M
9.62%
--
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
8.67M
9.02%
-138.19K
-1.57%
Jun 30, 2025
Samsara BioCapital, LLC
5.61M
5.91%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.70M
5.93%
-329.09K
-5.46%
Jun 30, 2025
The Vanguard Group, Inc.
4.85M
5.04%
+16.39K
+0.34%
Jun 30, 2025
Redmile Group, LLC
3.93M
4.09%
-469.24K
-10.67%
Jun 30, 2025
State Street Investment Management (US)
3.07M
3.2%
-59.84K
-1.91%
Jun 30, 2025
Bellevue Asset Management AG
2.95M
3.07%
+440.40K
+17.57%
Jun 30, 2025
Eventide Asset Management, LLC
2.91M
3.03%
+251.64K
+9.45%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
iShares Neuroscience and Healthcare ETF
4.92%
Roundhill GLP-1 & Weight Loss ETF
2.65%
Amplify Weight Loss Drug & Treatment ETF
1.38%
SPDR S&P Biotech ETF
1.35%
Virtus LifeSci Biotech Clinical Trials ETF
0.81%
Direxion Daily S&P Biotech Bull 3X Shares
0.71%
Tema Heart & Health ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.49%
ProShares Ultra Nasdaq Biotechnology
0.37%
Invesco Nasdaq Biotechnology ETF
0.36%
查看更多
iShares Neuroscience and Healthcare ETF
占比4.92%
Roundhill GLP-1 & Weight Loss ETF
占比2.65%
Amplify Weight Loss Drug & Treatment ETF
占比1.38%
SPDR S&P Biotech ETF
占比1.35%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.81%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.71%
Tema Heart & Health ETF
占比0.69%
JPMorgan Healthcare Leaders ETF
占比0.49%
ProShares Ultra Nasdaq Biotechnology
占比0.37%
Invesco Nasdaq Biotechnology ETF
占比0.36%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
